Please assess the completion status of the following clinical trial:

Trial Title: A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Have given written informed consent~2. Males or females aged 18 to 70 years old at the time of first dosing~3. Have a body mass index (BMI) of \>25.0 and ≤ 45.0 kg/m2 at Screening~4. Have a documented history of hypercholesterolemia, defined as LDL-C ≥ 2.59 mmol/L~Exclusion Criteria:~1. The use of any anti-dyslipidemia agent within 28 days prior to dosing~2. History of a total cholesterol ≥ 10.35 mmol/L or triglyceride ≥ 11.3 mmol/L~3. History of a clinically significant cardiac arrhythmia or clinically significant abnormal ECG results at Screening~4. Significant peripheral or coronary vascular disease~5. Clinically significant abnormal blood pressure at Screening or Baseline, defined as supine blood pressure ≥160/100 mmHg, or ≤ 90/60 mmHg~6. Primary hypothyroidism (thyroid stimulating hormone \[TSH\] \> upper limit or normal \[ULN\] and free T4 \< lower limit of normal \[LLN\]), primary subclinical hypothyroidism (screening TSH \> ULN and free T4 within normal limits \[WNL\]), or secondary hypothyroidism (screening TSH \< LLN and free T4\< LLN) at Screening~7. Glucose-6-phosphate dehydrogenase (G6PD) deficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- HTD1801 250 mg BID (Type: EXPERIMENTAL): Subjects received 500 mg/day HTD1801
- HTD1801 500 mg BID (Type: EXPERIMENTAL): Subjects received 1000 mg/day HTD1801
- HTD1801 1000 mg BID (Type: EXPERIMENTAL): Subjects received 2000 mg/day HTD1801
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).